International
The Morning Science

What science found today

‹
 

Launch

First siRNA Therapy Approved for Myasthenia Gravis

MedPage Today ·

First siRNA Therapy Approved for Myasthenia Gravis

The Brief

  • The FDA approved subcutaneous cemdisiran, branded Livsayis, for generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody-positive.
  • Cemdisiran is a small interfering RNA (siRNA) therapy, the first siRNA treatment approved for myasthenia gravis according to the headline.
  • The approval was announced by Regeneron.

Why it matters

It establishes siRNA, a gene-silencing approach, as a clinically approved option for an autoimmune neuromuscular disease, which may matter for other antibody-mediated conditions being studied with similar therapies.

Who’s affected

  • adults with generalized myasthenia gravis who are AChR antibody-positive
  • neurologists and other clinicians treating myasthenia gravis

(MedPage Today) -- The FDA approved subcutaneous cemdisiran (Livsayis), a small interfering RNA (siRNA) therapy, to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody-positive, Regeneron announced...

How do you feel about this?

0 Comments

    First siRNA Therapy Approved for Myasthenia Gravis – The Morning Science